scholarly article | Q13442814 |
P819 | ADS bibcode | 2007PNAS..104.9788D |
P356 | DOI | 10.1073/PNAS.0703584104 |
P932 | PMC publication ID | 1887550 |
P698 | PubMed publication ID | 17535926 |
P5875 | ResearchGate publication ID | 6300004 |
P50 | author | Brian R. Murphy | Q65658906 |
P2093 | author name string | Alexander Bukreyev | |
Joshua M DiNapoli | |||
Lijuan Yang | |||
Peter L Collins | |||
Siba K Samal | |||
Subbiah Elankumaran | |||
Alexander Kotelkin | |||
P2860 | cites work | Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited | Q24531423 |
An outbreak of conjunctivitis due to Newcastle disease virus (NDV) occurring in poultry workers | Q24684635 | ||
THE CUTTER INCIDENT. POLIOMYELITIS FOLLOWING FORMALDEHYDE- INACTIVATED POLIOVIRUS VACCINATION IN THE UNITED STATES DURING THE SPRING OF 1955. II. RELATIONSHIP OF POLIOMYELITIS TO CUTTER VACCINE | Q28190886 | ||
Identification of a novel coronavirus in patients with severe acute respiratory syndrome | Q29615907 | ||
A novel coronavirus associated with severe acute respiratory syndrome | Q29617553 | ||
Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. | Q30357521 | ||
Review of accidents caused by incomplete inactivation of viruses | Q30421151 | ||
Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine | Q33230687 | ||
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice | Q33696283 | ||
Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. | Q33834543 | ||
Recombinant Newcastle disease virus as a vaccine vector | Q33850246 | ||
Newcastle disease and other avian paramyxoviruses | Q33997603 | ||
Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates | Q34092801 | ||
Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. | Q34294068 | ||
Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector | Q34302198 | ||
Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies | Q34438091 | ||
Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic | Q34465213 | ||
Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease | Q34624713 | ||
Nonsegmented negative-strand viruses as vaccine vectors | Q35139219 | ||
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity | Q36449078 | ||
Immunological characterization of the spike protein of the severe acute respiratory syndrome coronavirus | Q37421234 | ||
Newcastle disease virus V protein is a determinant of host range restriction | Q39864222 | ||
Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization | Q40108339 | ||
Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine | Q40393493 | ||
Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats | Q40397313 | ||
Role of fusion protein cleavage site in the virulence of Newcastle disease virus | Q40612116 | ||
Recovery of a virulent strain of newcastle disease virus from cloned cDNA: expression of a foreign gene results in growth retardation and attenuation | Q40735127 | ||
An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine | Q40940832 | ||
Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung. | Q42098075 | ||
SARS vaccine protective in mice | Q42555546 | ||
Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans | Q43000500 | ||
A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. | Q44110039 | ||
Infectious diseases. Mounting lab accidents raise SARS fears | Q44274438 | ||
Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice | Q44961556 | ||
Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets | Q45501850 | ||
Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. | Q45622393 | ||
Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity | Q45736005 | ||
Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus | Q45858547 | ||
Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys | Q47812425 | ||
Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. | Q50787284 | ||
Effects of a SARS-associated coronavirus vaccine in monkeys. | Q51639488 | ||
Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus | Q57769050 | ||
P433 | issue | 23 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | vaccine | Q134808 |
Newcastle disease virus | Q327082 | ||
immunization | Q1415366 | ||
vector-borne disease | Q2083837 | ||
Newcastle disease | Q11903425 | ||
emerging pathogen | Q108429945 | ||
P304 | page(s) | 9788-9793 | |
P577 | publication date | 2007-05-29 | |
P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
P1476 | title | Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens | |
P478 | volume | 104 |
Q35112976 | A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen. |
Q28261383 | Avian Paramyxovirus: A Brief Review |
Q92640537 | Characterization of thermostable Newcastle disease virus recombinants expressing the hemagglutinin of H5N1 avian influenza virus as bivalent vaccine candidates |
Q39498475 | Chimeric rabies glycoprotein with a transmembrane domain and cytoplasmic tail from Newcastle disease virus fusion protein incorporates into the Newcastle disease virion at reduced levels |
Q37297096 | Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans |
Q34427532 | Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells in vivo |
Q36949597 | Engineered intermonomeric disulfide bonds in the globular domain of Newcastle disease virus hemagglutinin-neuraminidase protein: implications for the mechanism of fusion promotion |
Q89860924 | Engineering of Live Chimeric Vaccines against Human Metapneumovirus |
Q36481537 | Enhanced Immune Responses to HIV-1 Envelope Elicited by a Vaccine Regimen Consisting of Priming with Newcastle Disease Virus Expressing HIV gp160 and Boosting with gp120 and SOSIP gp140 Proteins |
Q45354645 | Establishment of reverse genetics system for infectious bronchitis virus attenuated vaccine strain H120. |
Q35886963 | Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus |
Q35077454 | Evaluation of the Newcastle disease virus F and HN proteins in protective immunity by using a recombinant avian paramyxovirus type 3 vector in chickens |
Q30427591 | Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses |
Q41919169 | Expression of transgenes from newcastle disease virus with a segmented genome |
Q41325120 | Generation and evaluation of a recombinant genotype VII Newcastle disease virus expressing VP3 protein of Goose parvovirus as a bivalent vaccine in goslings |
Q36190495 | Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. |
Q33490614 | Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses |
Q39322307 | Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients |
Q33886452 | Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus |
Q34457996 | Induction of type I interferon secretion through recombinant Newcastle disease virus expressing measles virus hemagglutinin stimulates antibody secretion in the presence of maternal antibodies |
Q34808109 | Infectious Bronchitis Virus as a Vector for the Expression of Heterologous Genes |
Q40368584 | Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus |
Q38953230 | Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy |
Q36692742 | Modified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickens |
Q35883750 | Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges |
Q26744220 | Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines |
Q57169065 | Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis |
Q39056306 | Newcastle disease vaccines-A solved problem or a continuous challenge? |
Q35275117 | Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs |
Q34059360 | Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice |
Q40095159 | Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines. |
Q35140435 | Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats |
Q30382650 | Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. |
Q37535829 | Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer |
Q38192846 | Newcastle disease virus: current status and our understanding |
Q37033299 | Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses |
Q47164675 | Pigeon paramyxovirus type 1 from a fatal human case induces pneumonia in experimentally infected cynomolgus macaques (Macaca fascicularis). |
Q54967512 | Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer. |
Q97646303 | Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development |
Q38266413 | RNA-based viral vectors |
Q57989514 | Recombinant Live Vaccines to Protect Against the Severe Acute Respiratory Syndrome Coronavirus |
Q52717318 | Recombinant Newcastle disease virus (NDV) expressing Duck Tembusu virus (DTMUV) pre-membrane and envelope proteins protects ducks against DTMUV and NDV challenge. |
Q24602728 | Recombinant Newcastle disease virus as a vaccine vector for cancer therapy |
Q37133496 | Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model |
Q41925230 | Recombinant Newcastle disease virus rL-RVG enhances the apoptosis and inhibits the migration of A549 lung adenocarcinoma cells via regulating alpha 7 nicotinic acetylcholine receptors in vitro |
Q38559266 | Recombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases |
Q37304963 | Recombinant lentogenic Newcastle disease virus expressing Ebola virus GP infects cells independently of exogenous trypsin and uses macropinocytosis as the major pathway for cell entry |
Q30380898 | Recombinant vectors as influenza vaccines. |
Q40341670 | Rescue of a recombinant Newcastle disease virus strain R2B expressing green fluorescent protein |
Q39074984 | Rescue of recombinant Newcastle disease virus from cDNA. |
Q36190519 | Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response |
Q28533970 | Retracted: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector |
Q35018292 | Retracted: Evaluation of the Replication, Pathogenicity, and Immunogenicity of Avian Paramyxovirus (APMV) Serotypes 2, 3, 4, 5, 7, and 9 in Rhesus Macaques |
Q33828508 | Retracted: Experimental Infection of Mice with Avian Paramyxovirus Serotypes 1 to 9 |
Q40200048 | Reverse Genetics of Newcastle Disease Virus |
Q37386899 | Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. |
Q39877530 | Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector |
Q37524036 | SARS vaccines: where are we? |
Q35498222 | Safety and clinical usage of newcastle disease virus in cancer therapy |
Q82975260 | Severe acute respiratory syndrome (SARS) |
Q40592880 | The Threat and Response to Infectious Diseases (Revised). |
Q93199923 | Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains |
Q42758269 | What are the risks--hypothetical and observed--of recombination involving live vaccines and vaccine vectors based on nonsegmented negative-strain RNA viruses? |
Search more.